Grifols, S.A.
GRFSHealthcare|Drug Manufacturers - General|ES
$8.43
-0.03 (-0.35%)
DCF Value
$17.65
Tangible Book / Share
$12.11
Graham Number
$11.70
Cash / Share
$1.02
Clinical Trials (32)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT00968695 Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites. | Cirrhosis, Ascites | P4 | Completed | 33 | Open-label | Albumin |
| NCT02472665 Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease | Von Willebrand Disease | P4 | Withdrawn | — | Open-label | plasma-derived FVIII/VWF concentrate |
| NCT00634569 Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects | Primary Immune Deficiency Disease | P4 | Completed | 24 | Open-label | Flebogamma 5% DIF |
| NCT00699140 Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura | Immune (Idiopathic) Thrombocytopenic Purpura | P3 | Completed | 18 | Open-label | IGIV3I Grifols |
| NCT00319228 Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate | Antithrombin III Deficiency | P2P3 | Terminated | 3 | Open-label | Plasma-derived AT-III concentrate |
| NCT03702920 Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% | Acute-On-Chronic Liver Failure | P3 | Terminated | 274 | RCT, Open-label | SMT + PE-A 5% |
| NCT03451292 Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites | Decompensated Cirrhosis and Ascites | P3 | Completed | 410 | RCT, Open-label | Albutein 20% |
| NCT00511147 IGIV Study for Chronic ITP Patients Ages 3-70 | Idiopathic Thrombocytopenic Purpura | P3 | Completed | 64 | Open-label | IGIV3I Grifols 10% |
| NCT03461406 A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants | Excessive Bleeding During Surgery | P3 | Completed | 186 | RCT, Single-blind | Fibrin Sealant Grifols, EVICEL |
| NCT00684047 Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis | Target Bleeding Site During Peripheral Vascular Surgery | P2P3 | Completed | 239 | RCT, Single-blind | FS Grifols, FS Grifols |
| NCT00838071 Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation | Hepatitis B, Chronic | P3 | Completed | 20 | Open-label | Specific intravenous anti-hepatitis B immunoglobulin |
| NCT03869385 Albumin Replacement Therapy in Septic Shock | Septic Shock | P3 | Terminated | 440 | RCT, Single-blind | Albutein® 200 g/L or Plasbumin® 20 |
| NCT01662856 Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery | Vascular Surgical Bleeding | P3 | Completed | 225 | RCT | Fibrin Sealant Grifols |
| NCT02176863 Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome | Post-polio Syndrome | P2P3 | Terminated | 191 | RCT, Double-blind | Flebogamma® 5% DIF, Placebo |
| NCT01131065 Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients | Hepatitis B, Liver Transplantation | P3 | Completed | 15 | Open-label | Hepatitis B immune globulin |
| NCT04636268 FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis | Congenital Afibrinogenemia, Hypofibrinogenemia | P3 | Withdrawn | — | Open-label | FIB Grifols |
| NCT01561053 A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease | Alzheimer's Disease | P2P3 | Completed | 347 | RCT, Double-blind | Albumin 5%, Albumin 20%, Immunoglobulin |
| NCT01754480 Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries | Parenchymous Tissue Surgical Bleeding | P3 | Completed | 325 | RCT | Fibrin Sealant Grifols |
| NCT01731938 Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries | Soft Tissue Surgical Bleeding | P3 | Completed | 327 | RCT, Single-blind | Fibrin Sealant (FS) Grifols |
| NCT04547127 A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) | COVID-19 | P2 | Completed | 200 | RCT, Open-label | Convalescent anti-SARS-CoV-2 MBT Plasma, Standard Medical Treatment |
| NCT04432324 Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19) | COVID-19 | P2 | Completed | 100 | RCT, Open-label | Intravenous Immune Globulin, Standard Medical Treatment |
| NCT02479802 Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | P2 | Completed | 13 | Open-label | Albumin |
| NCT00823082 Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass | Acquired Antithrombin III Deficiency, Coronary Artery Bypass | P2 | Completed | 200 | RCT, Single-blind | Antithrombin III |
| NCT04495101 Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19 | COVID-19 | P2 | Completed | 100 | RCT, Open-label | Prolastin, Standard Medical Treatment |
| NCT07264517 Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). | Dry Eye Disease | P2 | Completed | 103 | RCT, Double-blind | GRF312 5% |
| NCT00895713 Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation | Hepatitis B, Chronic | P2 | Completed | 18 | Open-label | intramuscular hepatitis B virus immune globulin |
| NCT02014402 Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery | Hemostasis | P2 | Completed | 181 | RCT, Double-blind | Human thrombin, Bovine thrombin |
| NCT03585257 HEAL STUDY (Hepatic Encephalopathy and Albumin Study) | Cirrhosis, Hepatic Encephalopathy | P2 | Completed | 48 | RCT, Double-blind | 25% IV albumin |
| NCT02281500 Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia | Congenital Afibrinogenemia | P1P2 | Completed | 24 | Open-label | Human Plasma-Derived Fibrinogen Concentrate |
| NCT00742417 Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid | Alzheimer's Disease | P2 | Completed | 42 | RCT, Double-blind | Albutein 5% |
| NCT01201720 Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure" | Liver Cirrhosis, Liver Failure | N/A | Completed | 12 | Open-label | — |
| NCT04356781 Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing | Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Completed | 20 | — | — |